1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Neuraltus Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Neuraltus Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

Neuraltus Pharmaceuticals, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Neuraltus Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Neuraltus Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Neuraltus Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Neuraltus Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Neuraltus Pharmaceuticals, Inc. - Brief Neuraltus Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Neuraltus Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Neuraltus Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Neuraltus Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Neuraltus Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Neuraltus Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Neuraltus Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Neuraltus Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Neuraltus Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Neuraltus Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Neuraltus Pharmaceuticals, Inc. Snapshot 4
Neuraltus Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Neuraltus Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Neuraltus Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Neuraltus Pharmaceuticals, Inc. - Pipeline Products Glance 9
Neuraltus Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Neuraltus Pharmaceuticals, Inc. - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Neuraltus Pharmaceuticals, Inc. - Drug Profiles 11
NP-001 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
NP-003 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Neuraltus Pharmaceuticals, Inc. - Pipeline Analysis 14
Neuraltus Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 14
Neuraltus Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 15
Neuraltus Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 16
Neuraltus Pharmaceuticals, Inc. - Recent Pipeline Updates 17
Neuraltus Pharmaceuticals, Inc. - Dormant Projects 18
Neuraltus Pharmaceuticals, Inc. - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables


Neuraltus Pharmaceuticals, Inc., Key Information 4
Neuraltus Pharmaceuticals, Inc., Key Facts 4
Neuraltus Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Neuraltus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Neuraltus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Neuraltus Pharmaceuticals, Inc. - Phase II, 2013 9
Neuraltus Pharmaceuticals, Inc. - Pre-Clinical, 2013 10
Neuraltus Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 14
Neuraltus Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 15
Neuraltus Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 16
Neuraltus Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 17
Neuraltus Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 18

List of Figures


Neuraltus Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Neuraltus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Neuraltus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Neuraltus Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 14
Neuraltus Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 15
Neuraltus Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.